戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 xyphenyl)-4,5-dihydro-4,4,5,5-tetramethyl-1H-imidazolyl-1-oxy-3-oxide (carboxy-PTIO, an NO scavenger)
2 potent compound is methyl (2E,4E,6E,8E)-9-(3-imidazolyl-2,6,6-trimethylcyclohex-1-enyl)-3,7-dimethyl
3 ymer {[Mn2(NITIm)3]ClO4}n (1) (NITImH = 2-(2-imidazolyl)-4,4,5,5-tetramethyl-4,5-dihydro-1H-3-oxide-1
4  17alpha-hydroxylase/C17,20-lyase, 17beta-(4-imidazolyl)-5-pregnen-3beta-ol, was also able to inhibit
5 ither imidazole nitrogen, 1e, a di(isopropyl)imidazolyl analogue of 1b was made along with its doubly
6                         Carbohydrate-derived imidazolyl and triazolyl thiourethanes with such accepto
7 e, without an internally appended axial base imidazolyl), as determined from reactivity comparison of
8 abricated based on platinum(II) bis(N-methyl-imidazolyl)benzene chloride (Pt-16).
9 addition of iodoalkanes to sodium tetrakis(1-imidazolyl)borate (NaBIm(4)).
10 zolyl)borate or hydrogen tetrakis(4-methyl-1-imidazolyl)borate in a concentrated ammonium hydroxide s
11 (3))(4)Pd(NO(3))(2)] and hydrogen tetrakis(1-imidazolyl)borate or hydrogen tetrakis(4-methyl-1-imidaz
12 ce of counterion, i.e. bromide vs tetrakis(1-imidazolyl)borate.
13                                        omega-Imidazolyl carboxylic acids (C10-C12) have been used as
14 ants of the modified 38C2 and the Cu(II)-bis-imidazolyl complex k(6-CuCl2) gives a rate enhancement o
15 bitors of P450(17 alpha), whereas the 17-(2'-imidazolyl) compound (9b) was one of the most potent inh
16 upling strategy is used to construct the bis-imidazolyl core skeleton.
17                                          10-(Imidazolyl)decanoic acid was the best inhibitor (Kic = 0
18                           The binding of 10-(imidazolyl)decanoic acid was too tight for an absolute K
19  omega-imidazolyl-octanoic fatty acid, omega-imidazolyl-decanoic fatty acid, and omega-imidazolyl-dod
20           We found that CLT and a stable des-imidazolyl derivative inhibited directly two pharmacolog
21                               The 17 beta-(4'imidazolyl) derivatives (2a, 2e, 4a, 4c) were found to b
22                           A number of 17-(4'-Imidazolyl) derivatives were prepared by condensing the
23                             Among the 17-(4'-imidazolyl) derivatives, introduction of the 17 alpha-hy
24  amino acid unsymmetrical urea A and carboxy-imidazolyl-dipeptide ester B intermediates.
25    The nonpolar nature of such doubly masked imidazolyl-dipyrromethanes facilitated handling.
26  HeLa cells treated with 1-methyl-1-propyl-2-imidazolyl disulfide (IV-2), a pharmacologic inhibitor o
27 study, we hypothesized that 1-methylpropyl 2-imidazolyl disulfide (IV-2), a thioredoxin (TRX) inhibit
28 mia clonogenic cells toward 1-methylpropyl 2-imidazolyl disulfide, an inhibitor of thioredoxin expres
29 ithiocarbonate, S-methyl xanthates, methyl N-imidazolyl dithioate, N-alkyl dithiocarbamate, and pheny
30 c = 0.9 microM, Kiu = 5.7 microM), while 12-(imidazolyl)dodecanoic acid (Kic = 1.35 microM, Kiu = 6.9
31 ga-imidazolyl-decanoic fatty acid, and omega-imidazolyl-dodecanoic fatty acid.
32 c) to alkynes 2a-s to synthesize the indolyl/imidazolyl enamines 3a-p, 5a-o, and 6a-e using superbasi
33 s of these inhibitors by attaching the omega-imidazolyl fatty acid to the nitrogen of an amino acid g
34                                        Omega-imidazolyl fatty acids have previously been found to be
35 erocycles and the coupling of one eta(2)-N,C-imidazolyl fragment with a coordinated 1-methylbenzimida
36 ors affecting the nucleophilic attack of the imidazolyl group on the phosphorus center of the substra
37 h an effective molarity up to 2900 M for the imidazolyl group, ruling out competition from external n
38           We report that attachment of the 4-imidazolyl group, via 1-, 2-, or 3-carbon alkyl or alkan
39 phyrinate P(Im) with its tethered axial base imidazolyl group.
40 CH(2)(S-tim)(2) (2) (where tim = thio(methyl)imidazolyl) has been reinvestigated in order to optimize
41  extra protein-like functionalities, namely, imidazolyl (histidine analogue) and primary amino (lysin
42 t are supported by tris(2-mercapto-1-t-butyl-imidazolyl)hydroborato ligation, namely [Tm(Bu(t))]HgEPh
43 donor moiety {D = benzyl (Bz); pyridyl (Py); imidazolyl (Im); dimethylamino (NMe(2)); (tert-butylphen
44 )bimiq1)](2+) (1c, where (Pr)bimiq1 = bis(3-(imidazolyl)isoquinolinyl)propane) emerges as a catalyst
45 hing and detaching the nitrogen atoms in its imidazolyl "legs" to and from the protruding close-packe
46  catalytic benefit to the binding of the bis-imidazolyl ligand into 38C2.
47                                          The imidazolyl-mesalazine ester-based Ru(II) complex 13 show
48                          Our work shows that imidazolyl-mesalazine ester-based Ru(II) complexes inhib
49 tions of both clotrimazole (CLT) and its des-imidazolyl metabolite, 2-chlorophenyl-bisphenyl-methanol
50               The modified nucleotides, a C5-imidazolyl-modified dUTP and 3-(aminopropynyl)-7-deaza-d
51                                  By using C5-imidazolyl-modified dUTPs together with 3-(aminopropynyl
52 simultaneous incorporation of both amino and imidazolyl moieties into a DNA molecule during PCR.
53 dinating heterocycles and, among them, the 4-imidazolyl moiety is the most convenient for the interac
54  described, comprising a simple divalent bis(imidazolyl) molecule that is shown to "walk" at room tem
55 analysis for this reaction a series of o-(2'-imidazolyl)naphthyl (4-nitrophenyl) phosphate isomers we
56 th apical positions occupied by the incoming imidazolyl nucleophile and the p-nitrophenolate leaving
57 analogs by cocrystallizing CYP2E1 with omega-imidazolyl-octanoic fatty acid, omega-imidazolyl-decanoi
58 ylamino]-3-[4-(1-methyl-4-trifluoromethyl -2-imidazolyl)phenoxy]-2-propanol dihydrochloride (CGP-2071
59 ylamino]-3-[4-(1-methyl-4-trifluoromethy l-2-imidazolyl)phenoxy]-2-propanol], which showed no agonist
60 hylamino]-3-[4-(1-methyl-4-trifluormet hyl-2-imidazolyl)-phenoxy]-2-propanolmethanesulfonate (CGP2071
61 hylamino]-3-[4-(1-methyl-4-trifluormet hyl-2-imidazolyl)-phenoxy]-2-propanolmethanesulphonate (CGP 20
62 tetraazacyclododedacane, tris(4,5-dimethyl-2-imidazolyl)phosphine, and tris(2-benzimidazolylmethyl)am
63 stidinol, NAD, and the alternative substrate imidazolyl propanediol demonstrated an essential base wi
64 urocanic acids), and the related fluorinated imidazolyl propenals and prop-2-en-1-ols, from urocanic
65 uence has been adapted to prepare 3-fluoro-3-imidazolyl-propenoic acids (beta-fluorourocanic acids),
66 eport the synthesis and activity of novel 17-imidazolyl, pyrazolyl, and isoxazolyl androstene derivat
67 eterocyclic substituents, including pyridyl, imidazolyl, pyrimdyl, and other groups.
68 also reveal that the respective cofragments (imidazolyl, pyrrolyl, and phenoxyl) are formed in very l
69 r phenyl group (2c) on the 2'-position of 4'-imidazolyl ring caused a dramatic decrease in the potenc
70                          We show here how an imidazolyl ring incorporated into a rotary switch based
71  the substituent groups on the cross-linking imidazolyl ring strikes a perfect balance with their por
72 aromatic moiety, for example, a pyrazolyl or imidazolyl ring to decrease CNS MPO scores in order to r
73 '-imidazolyl) ring (9a, 10) or a 20 beta-(2'-imidazolyl) ring (12), instead of the 17 beta-(4'-imidaz
74 zolyl) ring (12), instead of the 17 beta-(4'-imidazolyl) ring (2a, 4a), are weak inhibitors.
75 y properties, Compounds having a 17 beta-(2'-imidazolyl) ring (9a, 10) or a 20 beta-(2'-imidazolyl) r
76 b(5) reveals nearly orthogonal planes of the imidazolyl rings of heme-ligating residues His(89) and H
77 idin-4-yl)-1-hydroxypyrazole (4-PHP) 3- or 5-imidazolyl substituted analogues have been designed, syn
78 icroM, Kiu = 6.9 microM) was superior to 11-(imidazolyl)undecanoic acid (Kic = 7.5 microM, Kiu = 16 m